New 125i dosimetry in prostatic brachytherapy planning
Piermattei, A.
Rays 18(1): 58-62
1993
ISSN/ISBN: 0390-7740 PMID: 8356241 Document Number: 408629
Document emailed within 1 workday
Related Documents
Soares, C.G. 2002: Standards for intravascular brachytherapy dosimetry Cellular and Molecular Biology 48(5): 441-443Arcovito, G.; Piermattei, A.; Bacci, C.; Pittella, G.; Castagnola, M. 1985: Rigid phantom dosimetry of brachytherapy sources, with special reference to 125-I La Radiologia Medica 71(6): 426-432
Waksman, R. 1998: Intracoronary brachytherapy in the Cath Lab. Physics dosimetry, technology and safety considerations Herz 23(6): 401-406
Ippolito, C.; Spisani, L.; De Luca, G.; Romano, A.; Daniele, C.; Cartei, F.; Lavagnini, P.; Princivalle, S.; Lappi, S. 2002: Role of transrectal ultrasonography in prostatic brachytherapy Archivio Italiano di Urologia Andrologia: Organo Ufficiale di Societa Italiana di Ecografia Urologica e Nefrologica 74(4): 295-298
Kovács, G. 2000: A retrospective comparison of radical retropubic prostatectomy and of iodine-125 brachytherapy in localized prostatic carcinoma Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 176(3): 150
Kovács, G.; Hebbinghaus, D.; Dennert, P.; Kohr, P.; Wilhelm, R.; Kimmig, B. 1996: Conformal treatment planning for interstitial brachytherapy Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 172(9): 469-474
Blattmann, H.; Cabeza, L.; Haefeli, P.; Müller-Duysing, W.; Riehle, I. 1974: Planning of dosimetry on the pion beam piE3 as preliminaries of biological experiments and medical applications Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 121(1): 105-108
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Inoue, T.; Inoue, T.; Yoshioka, Y.; Yoshida, K. 2000: High-dose rate interstitial brachytherapy for mobile tongue cancer: Part 3. Comparative study of early mucosal reaction and late tongue atrophy between LDR and HDR Ir-192 interstitial brachytherapy for patients with carcinoma of the mobile tongue Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 296-300
Hodapp, N.; Hinkelbein, W.; Slanina, J.; Wannenmacher, M. 1984: Alternative use of the simulator method and computer tomography in planning radiotherapy for non-metastasizing prostatic cancer Der Radiologe 24(1): 19-23
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Svanholm, H.; Hørder, M. 1988: Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques Scandinavian Journal of Urology and Nephrology. Supplementum 107: 65-70
Cecchi, M.; Sepich, C.A.; Pagni, G.L.; Summonti, D.; Ippolito, C.; Di Benedetto, A.; Bertolini, L.; Minervini, R.; Fiorentini, L. 1998: Prostatic endoprosthesis in the treatment of prostatic obstruction: preliminary experience with the new Trestle model Chirurgia Italiana 50(1): 37-40
Vieillefond, A.; Berger, N.; Dauge-Geffroy, M.C.; Saint Andre, J.P. 1993: Prostatic adenosis and dysplasia. what is their definition... and their significance? Are there "precancerous" lesions in prostatic pathology? Annales de Pathologie 13(2): 85-87
Bouffioux, C. 1983: Prostatic cytology. Value of the technic in the diagnosis and surveillance of prostatic carcinomas; viewpoint of the urologist Acta Urologica Belgica 51(1): 56-71
Sáenz de Chirife, A.M.; Bassi, A.M.; Celeste, F.; Bergdolt, D. 1991: Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course Archivos Espanoles de Urologia 44(4): 405-409
Paul, B.D.; Serrano, J.A.; Friedman, A.E.; Sarlos, I.J.; Sternberger, N.J.; Wasserkrug, H.L.; Seligman, A.M. 1977: New agents for prostatic cancer activated specifically by prostatic acid phosphatase Cancer Treatment Reports 61(2): 259-263
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Rodríguez Rodríguez, R.; Mayayo Dehesa, T.; Galbis Sanjuan, F.; Burgos Revilla, F.J.; Jiménez Cidre, M.; García González, R. 1996: Chronic prostatic inflammation: a confounding factor in the diagnosis of prostatic cancer Archivos Espanoles de Urologia 49(7): 669-673